Biogen's Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst | FiercePharma
Biogen's Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst
“The public supports CMS’ decision, which would limit Medicare coverage for antibeta-amyloid drugs like Aduhelm to patients enrolled in approved clinical studies, according to a BofA Securities analysis of more than 1,000 comments received by CMS.
There were thrice as many comments in support of CMS’ National Coverage Determination (NCD) and questioning Aduhelm’s efficacy as there were comments asking for a proposal tweak, BofA’s Geoff Meacham wrote in a note to clients Tuesday.
Among commenters who were skeptical of Aduhelm (or supportive of CMS’ decision), 93% questioned the drug’s benefit. Many also pushed back on Aduhelm’s price tag, the BofA team said.”
Biogen's Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst
“The public supports CMS’ decision, which would limit Medicare coverage for antibeta-amyloid drugs like Aduhelm to patients enrolled in approved clinical studies, according to a BofA Securities analysis of more than 1,000 comments received by CMS.
There were thrice as many comments in support of CMS’ National Coverage Determination (NCD) and questioning Aduhelm’s efficacy as there were comments asking for a proposal tweak, BofA’s Geoff Meacham wrote in a note to clients Tuesday.
Among commenters who were skeptical of Aduhelm (or supportive of CMS’ decision), 93% questioned the drug’s benefit. Many also pushed back on Aduhelm’s price tag, the BofA team said.”